Arrowhead制药 ARWR 深 沪
已收盘 09-12 16:00:00 美东时间
29.72
0.000
0.00%
华盛通- 最 高31.13
- 今 开29.65
- 成交量 304.52万股
- 最 低 29.51
- 昨 收 29.72
- 总市值 41.01亿
- 52周最高 31.13
- 市盈率 静 --
- 换手率 2.21%
- 52周最低 9.57
- 委 比 80.69%
- 总股本 1.38亿
- 历史最高 93.66
- 量 比 1.11
- 振 幅 5.45%
- 历史最低 1.22
- 每 手 1
- 风险率 4.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arrowhead Pharmaceuticals Sues Ionis Over Patent Dispute
Arrowhead Pharmaceuticals ( ($ARWR) ) has provided an announcement. On Septembe...
09-11 20:00
Arrowhead Pharma Files Request For Regulatory Clearance To Initiate Phase 1/2a Clinical Trial Of ARO-MAPT, Investigational RNAi Therapeutic For Tauopathies
- In preclinical studies presented today at the RNA Leaders USA Congress 2025, investigational ARO-MAPT demonstrated potent and long-lasting MAPT mRNA and Tau protein suppression with uniform distribution
09-10 19:31
美股周涨跌榜 | 医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%
医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%，肺纤维化治疗取得重大突破；Lululemon周跌17%，此前下调年度利润及销售额预期>>
09-06 10:02
美股大行评级 | 潜在涨幅91.64%！曼恩凯德生物医疗获HC Wainwright升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持曼恩凯德生物医疗"买入"评级，目标价从9美元升至11美元；杰富瑞：维持Ionis Pharmaceuticals"买入"评级，目标价从83美元升至96美元
09-03 10:20
Arrowhead Pharmaceuticals Inks Global Licensing And Collaboration Agreement With Novartis For ARO-SNCA For Synucleinopathies, Such As Parkinson's Disease; Arrowhead Will Receive $200M As An Upfront Payment And Is Eligible To Receive Up To $2B In Milestone Payments Plus Commercial Sales Royalties
Upon closing, Arrowhead will receive an upfront payment of $200 millionNovartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead's preclinical stage siRNA therapy for the treatment of synucleinopathies,
09-02 19:32
Arrowhead Pharmaceuticals Redeems ~$50M Of Arrowhead Stock; Receives ~$50M In Cash In Satisfaction Of Milestone from Sarepta Therapeutics
- Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash
08-14 04:27
Arrowhead Pharmaceuticals’ Earnings Call Highlights Strategic Progress
Arrowhead Pharmaceuticals, Inc. (($ARWR)) has held its Q3 earnings call. Read o...
08-12 08:57
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
RBC Capital Maintains Outperform on Arrowhead Pharma, Lowers Price Target to $38
RBC Capital analyst Luca Issi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and lowers the price target from $40 to $38.
08-09 01:20
Arrowhead Pharma Q3 EPS $(1.26) Misses $(0.89) Estimate, Sales $27.767M Beat $23.711M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.89) by 41.57 percent. This is a 8.7 percent increase over losses of $(1.38) per share from
08-08 04:04
